Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (285)	9/24/2002 6:13:46 PM
From: keokalani'nui	Respond to of 625

Haven't changed my opinion on the clinical programs since Spring; except that I learned how small an indication scleraderma might actually be. True, it is surely a better price than when I said it was overvalued, eh? Message 17251424 Hopefully this recent shelacking is due to bad news in glaucoma and thus (this is the hopeful part) they will finally kill the project. Then, if ogsi also killed vavesca, I would finally forgive England for the Stamp Act. Seriously, I still own it, but would I recommend it to a friend? Hmmm. Not sure. Personally I am saving my last few dollars for a go-out-in-style last-gasp roman candle pressing on dovp, kosn, 3dp, regn, mlnm, rigl and tlrk. CAT isn't good enough to fit in that group IMO. I haven't done it yet because after I do there will be no need to visit SI anymore.